crysball,
You're absolutely right, management should be applauded for choosing the right direction once again. PARS' Tamoxifen project isn't a high risk project, as they try to improve an already approved drug (as opposed to discovering some novel compound, just according to their strategy like we all know).
PARS will seek a partner for Tamoxifen methiodide (or some other analog they find attractive) sooner than with HU211. They won't try to push the project all the way to PIII, they'll get a partner much sooner. In that sense, '99 could be very interesting, as we could sign a partner for Tamoxifen as well as HU211 - now that is some exposure !!!
PARS will try to do some sort of a PI/PII trial in '99, just to show some trends of efficacy and safety. This is supposed to attract a partner, who will push the project through larger scale clinical trials and, hopefully, all the way to FDA approval.
In any event, PARS and Ruder Finn can use this huge interest in breast cancer in general, and specifically in Tamoxifen to their advantage. Having a drug in the pipeline that exactly fits this huge need from the market, especially as the papers keep reporting about this need, is a great benefit to any company, not alone a small biotech like PARS.
PARS will become profitable next year, according to all the articles posted here, that makes them part of a small group ~30 companies out of ~300 public biotech companies. That alone makes them attractive and should help them pop on many radar screens next year. On top of this they have a very exciting pipeline with HU211 and Tamoxifen, and remember HU211 is not one drug (it's a family of compounds that can produce 2-5 different drugs, 3 of which blockbusters, i.e. TBI, stroke and MS).
All this for under $2 per share (market cap less than $75), which makes PARS one of the biggest bargains out there.
|
